Emerging therapies for antiplatelet inhibition


New developments in antiplatelet agents for prevention/reduction of atherothrombotic events in patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI) were presented by Dr Samuel R Money, Mayo Clinic, Phoenix, Arizona, at the VEITHsymposium, in November 2008. Clinical studies show that Prasugrel, Ticagrelor, Cangrelor, Portola (PRT060128), and NF449 may have significant potential in the management of patients with atherothrombotic disease.